Overview

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II study in previously untreated subjects with histologically or cytologically proven stage IIIB/IV NSCLC designed to determine the efficacy of first line treatment with carboplatin and cetuximab.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
ImClone LLC
Collaborator:
Bristol-Myers Squibb
Treatments:
Carboplatin
Cetuximab